Table 2.
Comparison of the experimental group and the control group at week 0.
| Areas | Peak pressure (kPa) | Maximum force (N) | Contact area (cm2) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| CAFO | PCAFO | P | CAFO | PCAFO | P | CAFO | PCAFO | P | |
| T1 | 90.0±19.5 | 59.0±26.1 | 0.012* | 93.0±21.8 | 95.9±44.0 | 0.912 | 10.0±1.3 | 16.4±4.8 | 0.112 |
| T2–T5 | 46.7±19.0 | 31.0±26.8 | 0.532 | 65.2±57.3 | 39.9±52.2 | 0.623 | 12.1±5.8 | 8.1±7.1 | 0.521 |
| M1 | 125.0±51.0 | 34.2±31.3 | 0.041* | 90.7±30.4 | 36.9±40.0 | 0.112 | 7.6±3.5 | 8.1±3.3 | 0.822 |
| M2 | 223.1±38.2 | 316.6±335.6 | 0.623 | 172.0±39.7 | 128.3±108.7 | 0.541 | 7.3±0.5 | 8.1±3.1 | 0.631 |
| M3 | 241.2±78.1 | 350.3±287.5 | 0.421 | 169.0±65.8 | 288.1±271.4 | 0.443 | 6.6±1.0 | 7.5±0.8 | 0.221 |
| M4 | 239.3±93.5 | 296.4±166.1 | 0.643 | 184.2±80.2 | 241.0±140.7 | 0.522 | 7.3±0.9 | 7.9±0.85 | 0.134 |
| M5 | 192.1±95.3 | 152.4±93.2 | 0.623 | 241.2±132.7 | 183.9±96.2 | 0.631 | 12.1±2.4 | 12.2±1.3 | 0.942 |
| MF | 119.2±21.6 | 61.2±67.0 | 0.212 | 396.0±143.0 | 314.2±416.0 | 0.714 | 31.8±8.9 | 42.6±10.8 | 0.221 |
| MH | 119±13.7 | 196±37.6 | 0.042* | 211.1±125.2 | 243.5±75.5 | 0.622 | 14.1±4.5 | 11.8±1.6 | 0.242 |
| LH | 128.2±29.3 | 207.1±47.2 | 0.021* | 220.9±162.8 | 220.2±73.2 | 0.942 | 12.7±4.8 | 10.1±1.4 | 0.232 |
*
P<0.05 is considered a significant difference; values are expressed as means ± standard deviation;
CAFO – customized AFO; PCAFO – pre-customized AFO; T1 – hallux; T2–T5 – toes 2–5; M1 – first metatarsal; M2 – second metatarsal; M3 – third metatarsal; M4 – fourth metatarsal; M5 – fifth metatarsal; MF – midfoot; MH – medial heel; LH – lateral heel.